Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is simply a commercial-stage pharmaceutical institution focused connected processing therapies for patients suffering from uncommon neurological diseases. The flagship commercialized merchandise is WAKIX (pitolisant), a first-in-class medicine approved by the FDA to dainty excessive daytime sleepiness oregon cataplexy successful big patients with narcolepsy. Pitolisant functions done a caller mechanics of enactment that increases histamine merchandise successful the encephalon to beforehand wakefulness. Harmony is actively moving to grow its marketplace footprint by seeking regulatory approvals for pediatric narcolepsy and exploring treatments for idiopathic hypersomnia and Prader-Willi syndrome.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) precocious posted awesome Q1 2026 fiscal results, which featured full revenues of $215.4 million, representing a 17% year-over-year maturation driven by the sustained adoption of WAKIX. Management reaffirmed its full-year 2026 nett gross guidance of implicit $1 billion, signaling durable commercialized momentum and unchangeable marketplace demand. The concern exhibits exceptional operating leverage, converting its top-line maturation into beardown currency procreation that comfortably funds its late-stage objective pipeline. Investors are peculiarly optimistic astir Harmony’s lifecycle absorption strategies for pitolisant and its newer pipeline assets.

While we admit the imaginable of HRMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Growth Stock Portfolio: 12 Stock Picks by Carl C. Icahn and Chris Rokos Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey connected Google News.